NATCOPHARM Share Price Performance
₹0
-976.90 (-100.00%)
Price ₹0
Fair Value₹1,220.00
Share Pricen/a
Narrative Update • Jul 01
NATCO Pharma Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 114 Fair Values set on narratives written by author
NATCOPHARM Community Narratives
AN
Fair Value
·Fair Value ₹1.22k 20.3% undervalued intrinsic discount
Global Healthcare Trends Will Expand Affordable Generics Amid Risks
1users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value
·Fair Value ₹1.02k 4.8% undervalued intrinsic discount
High-value R&D And South Africa Entry Will Shape Uncertain Outcomes
2users have liked this narrative
0users have commented on this narrative
51users have followed this narrative
AN
Fair Value
·Fair Value ₹712 36.6% overvalued intrinsic discount
Falling Revenues And Risky Diversifications Will Weaken Future Outlook
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
High-value R&D And South Africa Entry Will Shape Uncertain Outcomes
NATCO Pharma is trying to reduce its dependence on a few big medicines by pushing deeper into harder-to-make generics and expanding into new markets like South Africa. The big question is whether new launches can replace fading U.S. sales fast enough, while higher research spending and regulatory and pricing pressures stay under control.Read more
AN
₹1.02k
4.8% undervalued intrinsic discount
Fair Value
Revenue
3.06% p.a.
Profit Margin
25.81%
Future PE
22.6x
Price in 2029
₹1.45k
Global Healthcare Trends Will Expand Affordable Generics Amid Risks
NATCO Pharma looks set to lean harder into affordable medicines, using a new overseas platform and its own manufacturing to broaden where it sells and reduce reliance on a few aging products. The big question is whether new launches and deal-making can outrun tougher pricing in its largest market and the rising cost and uncertainty of drug approvals.Read more
AN
₹1.22k
20.3% undervalued intrinsic discount
Fair Value
Revenue
4.37% p.a.
Profit Margin
24.37%
Future PE
27.52x
Price in 2029
₹1.74k
Falling Revenues And Risky Diversifications Will Weaken Future Outlook
Key Takeaways Accelerating loss of key US revenue streams and mounting pricing pressures threaten profitability, with diversification efforts carrying execution risks and limited growth potential outside core markets. Rising R&D and compliance costs, without clear pipeline success, risk eroding returns and could further undermine long-term earnings amid escalating regulatory and supply chain challenges.Read more
AN
₹712
36.6% overvalued intrinsic discount
Fair Value
Revenue
-16.01% p.a.
Profit Margin
17.31%
Future PE
40.5x
Price in 2028
₹1.02k
Trending Discussion
Recently Updated Narratives
AN
NATCOPHARM: Future Oncology Upside And Margin Gains Will Meet Softer Expectations
Fair Value: ₹1.02k 4.8% undervalued intrinsic discount
51 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NATCOPHARM: Oncology And Diabetes Pipeline Will Drive Share Price Upside
Fair Value: ₹1.22k 20.3% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Falling Revenues And Risky Diversifications Will Weaken Future Outlook
Fair Value: ₹712 36.6% overvalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
NATCO Pharma Limited Key Details
About NATCOPHARM
- Founded
- 1981
- Employees
- 4199
- CEO
- WebsiteView website
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Recent NATCOPHARM News & Updates
Narrative Update • Jun 17
NATCOPHARM: Oncology And Diabetes Pipeline Will Drive Share Price Upside
Analysts have held their price target for NATCO Pharma steady at ₹1,220, citing only minor model tweaks to long term revenue growth, profit margin assumptions and future P/E multiples that do not materially shift their valuation view. What's in the News for NATCO Pharma Lupin and NATCO Pharma received approval from the United States Food and Drug Administration for NATCO's Abbreviated New Drug Application for Eribulin Mesylate Injection, 1 mg/2 mL single dose vials, a bioequivalent version of Halaven Injection of Eisai Inc.Narrative Update • Jun 02
